Database Query Results : Lycopene, ,

Lyco, Lycopene: Click to Expand ⟱
Features:
Lycopene is a naturally occurring carotenoid found predominantly in tomatoes and other red fruits and vegetables.

Antioxidant Properties:
-Lycopene is a powerful antioxidant. It helps neutralize free radicals, which can reduce oxidative stress—a factor implicated in cancer development. Possible concern about interfering with chemotherapy and radiation therapy. However this review disagrees.
Inflammation Reduction:
-Some studies suggest that lycopene may help lower levels of inflammation, another process linked to cancer progression

At supraphysiological or extremely high concentrations, lycopene may have the potential to switch from an antioxidant to a prooxidant role
-The prooxidant effect of lycopene has been observed under conditions of high oxygen tension. In vitro studies have suggested that in environments with elevated oxygen levels, lycopene might promote rather than neutralize the production of reactive oxygen species (ROS).
-The presence of metal ions (such as iron or copper) in the environment can catalyze reactions where antioxidants, including lycopene, contribute to oxidative processes. These metals can interact with lycopene, potentially leading to the formation of radicals.

The mevalonate pathway produces cholesterol and a variety of isoprenoids, which are important for maintaining cell membrane integrity, protein prenylation, and other essential cellular functions.
-One of the primary enzymes in this pathway is HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase), which is the target of statin drugs used for lowering cholesterol. Some studies suggest that lycopene might downregulate the activity of HMG-CoA reductase or other enzymes in the mevalonate pathway. By doing so, lycopene could potentially reduce the synthesis of cholesterol and isoprenoids that are necessary for rapid cell proliferation—an especially relevant aspect in cancer cells.

Lycopene typically used in a 100mg/day range for cancer (inhibition of the the Melavonate Pathway)
-also has antiplatelet aggregation capability.

-Note half-life 16–20 days.
BioAv Heat processing, especially when combined with a small amount of fat, significantly enhances lycopene’s bioaccessibility and absorption. (20% under optimal conditions)
Pathways:
- ROS usually goes down, but may go up or down depending on dose and environment
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : EMT↓, MMPs↓, MMP9↓, IGF-1↓, uPA↓, VEGF↓, ROCK1↓, FAK↓, RhoA↓, NF-κB↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : EZH2↓, P53↑, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Integrins↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells


Scientific Papers found: Click to Expand⟱
287- ALA,  HCA,  Lyco,    Metabolic treatment of cancer: intermediate results of a prospective case series
"highlight2" >PSA↓, one patient
"highlight2" >OS↑,

1566- betaCar,  Lyco,    Antioxidant and pro-oxidant effects of lycopene in comparison with beta-carotene on oxidant-induced damage in Hs68 cells
- in-vitro, Nor, HS68
"highlight2" >*ROS↑, beta-carotene is known to have pro-oxidant activity in vitro
"highlight2" >*ROS⇅, The present study in Hs68 cells demonstrates that lycopene can be either an antioxidant or a pro-oxidant depending on the oxidants used, and that lycopene and beta-carotene behave similarly under the in vitro oxidative conditions.
"highlight2" >*Dose?, Both the antioxidant and pro-oxidant effects of lycopene tended to be dose-dependent

3987- betaCar,  Lyco,    Carotenoid bioavailability is higher from salads ingested with full-fat than with fat-reduced salad dressings as measured with electrochemical detection
- Trial, AD, NA
"highlight2" >*eff↑, A substantially greater absorption of carotenoids was observed when salads were consumed with full-fat than with reduced-fat salad dressing.

3528- Lyco,    The Importance of Antioxidant Activity for the Health-Promoting Effect of Lycopene
- Review, Nor, NA - Review, AD, NA - Review, Park, NA
"highlight2" >*antiOx↑, the antioxidant effect of lycopene
"highlight2" >*ROS↓, Lycopene has the ability to reduce reactive oxygen species (ROS) and eliminate singlet oxygen, nitrogen dioxide, hydroxyl radicals, and hydrogen peroxide
"highlight2" >*BioAv↝, human body cannot synthesize lycopene. It must be supplied with the diet
"highlight2" >*Half-Life↑, half-life of lycopene in human plasma is 12–33 days
"highlight2" >*BioAv↓, bioavailability decreases with age and in the case of certain diseases
"highlight2" >*BioAv↑, heat treatment process of food increases the bioavailability of lycopene
"highlight2" >*cardioP↑, positive effect on cardiovascular diseases, including the regulation of blood lipid levels
"highlight2" >*neuroP↑, beneficial effects in nervous system disorders, including neurodegenerative diseases such as Parkinson′s disease and Alzheimer′s disease
"highlight2" >*H2O2↓, Lycopene has the ability to reduce reactive oxygen species (ROS) and eliminate singlet oxygen, nitrogen dioxide, hydroxyl radicals, and hydrogen peroxide
"highlight2" >*VitC↑, ability to regenerate non-enzymatic antioxidants such as vitamin C and E.
"highlight2" >*VitE↑,
"highlight2" >*GPx↑, increase in cardiac GSH-Px activity and an increase in cardiac GSH levels
"highlight2" >*GSH↑,
"highlight2" >*MPO↓, also a decrease in the level of cardiac myeloperoxidase (MPO), cardiac H2O2, and a decrease in cardiac glutathione S transferase (GSH-ST) activity.
"highlight2" >*GSTs↓,
"highlight2" >*SOD↑, increasing the activity of GSH-Px and SOD in the liver
"highlight2" >*NF-kB↓, reducing the expression of NF-κB mRNA in the heart
"highlight2" >*IL1β↓, decreased the level of IL-1β and IL-6 and increased the level of anti-inflammatory IL-10 in the heart
"highlight2" >*IL6↓,
"highlight2" >*IL10↑,
"highlight2" >*MAPK↓, inhibited the activation of the ROS-dependent pro-hypertrophic mitogen-activated protein kinase (MAPK) and protein kinase B (Akt) signaling pathways.
"highlight2" >*Akt↓,
"highlight2" >*COX2↓, decrease in the levels of pro-inflammatory mediators in heart: COX-2, TNF-α, IL-6, and IL-1β and an increase in the anti-inflammatory cardiac TGF-β1.
"highlight2" >*TNF-α↓,
"highlight2" >*TGF-β1↑,
"highlight2" >*NO↓, reduced NO levels in heart and cardiac NOS activity
"highlight2" >*GSR↑, increase in the level of cardiac and hepatic SOD, CAT, GSH, GPx, and glutathione reductase (GR)
"highlight2" >*NRF2↑, It also activated nuclear factor-erythroid 2 related factor 2 (Nrf2). This affected the downstream expression of HO-1 [97].
"highlight2" >*HO-1↑,
"highlight2" >*TAC↑, Researchers observed an increase in the liver in TAC and GSH levels and an increase in GSH-Px and SOD activity
"highlight2" >*Inflam↓, study showed that lycopene was anti-inflammatory
"highlight2" >*BBB↑, Lycopene is a lipophilic compound, which makes it easier to penetrate the blood–brain barrier.
"highlight2" >*neuroP↑, Lycopene had also a neuroprotective effect by restoring the balance of the NF-κB/Nrf2 pathway.
"highlight2" >*memory↑, lycopene on LPS-induced neuroinflammation and oxidative stress in C57BL/6J mice. The tested carotenoid prevented memory loss

3273- Lyco,    Lycopene
- Review, Var, NA
"highlight2" >antiOx↑, lycopene supplementation is associated with strong antioxidant effects, it has the potential to interfere with chemotherapy and radiation therapy
"highlight2" >ChemoSen↓,
"highlight2" >RadioS↓,

3274- Lyco,    Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, C4-2B
"highlight2" >Akt↓, enhanced antitumor effects of enzalutamide by lycopene may be related to the reduction of AR protein levels through lycopene-mediated inhibition of AKT/EZH2 pathway,
"highlight2" >EZH2↓,

3275- Lyco,    Multifaceted Effects of Lycopene: A Boulevard to the Multitarget-Based Treatment for Cancer
- Review, Var, NA
"highlight2" >TumCCA↑, lycopene impedes the progress of the cell cycle from the G1 to the S phase, primarily by diminishing the cyclin D and cyclin E levels.
"highlight2" >cycD1↓,
"highlight2" >cycE↓,
"highlight2" >CDK2↓, causes a subsequent inactivation of CDK4 and CDK2 through a reduced phosphorylation of Rb
"highlight2" >CDK4↓,
"highlight2" >P21↑, lycopene elevates CDK inhibitor, p21, and p53 (tumor suppressor) levels
"highlight2" >P53↑,
"highlight2" >GSK‐3β↓, Finally, GSK3β, p21, p27, Bad, caspase 9, and p53 (via Mdm2) are inactivated
"highlight2" >p27↓,
"highlight2" >Akt↓, lycopene inhibits AKT (protein kinase B) and mTOR
"highlight2" >mTOR↓,
"highlight2" >ROS↓, ability of lycopene to minimize ROS formation and mitigate oxidative stress
"highlight2" >MMPs↓, lycopene may decrease the activity of metalloproteinases of the matrix and prevent SK-Hep1 cellular adhesion, invasion, and migration
"highlight2" >TumCI↓,
"highlight2" >TumCMig↓,
"highlight2" >NF-kB↓, well-documented that lycopene inhibits NF-kB binding activity
"highlight2" >*iNOS↓, They also claimed that the lycopene caused a decline in the LPS-induced protein and mRNA expression of iNOS,
"highlight2" >*COX2↓, Lycopene can therefore decrease the gene expression of iNOS and COX-2 as a non-toxic agent via controlling pro-inflammatory genes
"highlight2" >lipid-P↓, suppress gastric cancer by multimodal mechanisms of reduction in lipid peroxidation, elevation in the levels of antioxidants, and enhanced GSH
"highlight2" >GSH↑,
"highlight2" >NRF2↑, Reportedly, lycopene is known to “upregulate” this ARE system via Nrf2 in vitro (HepG2 and MCF-7 cells)

3276- Lyco,    Lycopene modulates cellular proliferation, glycolysis and hepatic ultrastructure during hepatocellular carcinoma
- in-vivo, HCC, NA
"highlight2" >G6PD↓, Moreover, NDEA treatment caused a significant increase in liver G6PD activity in the NDEA group when compared to the control and LycT groups.
"highlight2" >PCNA↓, The LycT + NDEA group showed a significant decrease in mRNA expression of PCNA and Cyclin D1 when compared to the NDEA group
"highlight2" >cycD1↓,
"highlight2" >P21↑, A significant increase in the expression of p21 was observed in the LycT + NDEA group when compared to the contro
"highlight2" >Hif1a↓, Pre-treatment with LycT in NDEA-challenged mice resulted in a significant reduction in the expression of HIF-1α at week 24 when compared to the NDEA group
"highlight2" >Glycolysis↓, Moreover, significant reductions in the activities of glycolytic enzymes following LycT pre-treatment in NDEA-challenged mice were inversely related to HCC development.

3277- Lyco,    Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent
- Review, Var, NA
"highlight2" >antiOx↑, lycopene provides a strong antioxidant activity that is 100 times more effective than α-tocopherol and more than double effective that of β-carotene
"highlight2" >TumCP↓, In vivo and in vitro experiments have demonstrated that lycopene at near physiological levels (0.5−2 μM) could inhibit cancer cell proliferation [[22], [23], [24]], induce apoptosis [[25], [26], [27]], and suppress metastasis [
"highlight2" >Apoptosis↑,
"highlight2" >TumMeta↑,
"highlight2" >ChemoSen↑, lycopene can increase the effect of anti-cancer drugs (including adriamycin, cisplatin, docetaxel and paclitaxel) on cancer cell growth and reduce tumour size
"highlight2" >BioAv↓, low water solubility and bioavailability of lycopene
"highlight2" >Dose↝, The concentration of lycopene in plasma (daily intake of 10 mg lycopene) is approximately 0.52−0.6 μM
"highlight2" >BioAv↓, significant decrease in lycopene bioavailability in the elderly
"highlight2" >BioAv↑, oils and fats favours the bioavailability of lycopene [80], while large molecules such as pectin can hinder the absorption of lycopene in the small intestine due to their action on lipids and bile salt molecules
"highlight2" >SOD↑, GC: 50−150 mg/kg BW/day ↑SOD, CAT, GPx ↑IL-2, IL-4, IL-10, TNF-α ↑IgA, IgG, IgM ↓IL-6
"highlight2" >Catalase↑,
"highlight2" >GPx↑,
"highlight2" >IL2↑, lycopene treatment significantly enhanced blood IL-2, IL-4, IL-10, TNF-α levels and reduced IL-6 level in a dose-dependent manner.
"highlight2" >IL4↑,
"highlight2" >IL1↑,
"highlight2" >TNF-α↑,
"highlight2" >GSH↑, GC: ↑GSH, GPx, GST, GR
"highlight2" >GPx↑,
"highlight2" >GSTA1↑,
"highlight2" >GSR↑,
"highlight2" >PPARγ↑, ↑GPx, SOD, MDA ↑PPARγ, caspase-3 ↓NF-κB, COX-2
"highlight2" >Casp3↑,
"highlight2" >NF-kB↓,
"highlight2" >COX2↓,
"highlight2" >Bcl-2↑, AGS cells Lycopene 5 μM ↑Bcl-2 ↓Bax, Bax/Bcl-2, p53 ↓Chk1, Chk2, γ-H2AX, DNA damage ↓ROS Phase arrest
"highlight2" >BAX↓,
"highlight2" >P53↓,
"highlight2" >CHK1↓,
"highlight2" >Chk2↓,
"highlight2" >γH2AX↓,
"highlight2" >DNAdam↓,
"highlight2" >ROS↓,
"highlight2" >P21↑, CRC: ↑p21 ↓PCNA, β-catenin ↓COX-2, PGE2, ERK1/2 phosphorylated
"highlight2" >PCNA↓,
"highlight2" >β-catenin/ZEB1↓,
"highlight2" >PGE2↓,
"highlight2" >ERK↓,
"highlight2" >cMyc↓, AGS cells: ↓Wnt-1, c-Myc, cyclin E ↓Jak1/Stat3, Wnt/β-catenin alteration ↓ROS
"highlight2" >cycE↓,
"highlight2" >JAK1↓,
"highlight2" >STAT3↓,
"highlight2" >SIRT1↑, Huh7: ↑SIRT1 ↓Cells growth ↑PARP cleavage ↓Cyclin D1, TNFα, IL-6, NF-κB, p65, STAT3, Akt activation ↓Tumour multiplicity, volume
"highlight2" >cl‑PARP↑,
"highlight2" >cycD1↓,
"highlight2" >TNF-α↓,
"highlight2" >IL6↓,
"highlight2" >p65↓,
"highlight2" >MMP2↓, SK-Hep1 human hepatoma cells Lycopene 5, 10 μM ↓MMP-2, MMP-9 ↓
"highlight2" >MMP9↓,
"highlight2" >Wnt↓, AGS cells Lycopene 0.5 μM, 1 μM ↓Wnt-1, c-Myc, cyclin E ↓Jak1/Stat3, Wnt/β-catenin alteration ↓ROS

3278- Lyco,    Anti-inflammatory effect of lycopene in SW480 human colorectal cancer cells
- in-vitro, Colon, SW480
"highlight2" >TNF-α↓, In cells treated with lycopene and LPS, the mRNA expression of TNF-α, IL-1β, IL-6, iNOS, and COX-2 were decreased significantly in a dose-dependent manner
"highlight2" >IL1β↓,
"highlight2" >IL6↓,
"highlight2" >iNOS↓,
"highlight2" >COX2↓,
"highlight2" >PGE2↓, The concentrations of PGE2 and NO decreased according to the lycopene concentration
"highlight2" >NO↓,
"highlight2" >NF-kB↓, The protein expressions of NF-κB and JNK were decreased significantly according to lycopene concertation
"highlight2" >JNK↓,
"highlight2" >Inflam↓, Lycopene was found to have anti-inflammatory effects in a rat model
"highlight2" >MPO↓, decreased myeloperoxidase (MPO) activity, as a marker of inflammation,

3279- Lyco,    The role of lycopene and its derivatives in the regulation of transcription systems: implications for cancer prevention
- Review, Var, NA
"highlight2" >chemoP↑, molecular mechanisms whereby lycopene and other carotenoids may exert their chemoprotective effects

3280- Lyco,    Lycopene as A Carotenoid Provides Radioprotectant and Antioxidant Effects by Quenching Radiation-Induced Free Radical Singlet Oxygen: An Overview
- Review, Var, NA
"highlight2" >*radioP↑, Studies have designated lycopene to be an effective radio-protector with negligible side effects.
"highlight2" >*antiOx↑, Antioxidant and radioprotective effects of lycopene
"highlight2" >*lipid-P↓, Pretreatment of lycopene to ã-irradiated lymphocytes resulted in decreased lipid peroxidation and improved antioxidant status which prevented damage to the lymphocytes

3281- Lyco,  Chemo,    Lycopene Supplementation for Patients Under Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Review, Var, NA
"highlight2" >eff↑, Our study shows that lycopene supplementation does not modify the main hallmarks of cancer, but it increases circulating lycopene concentration in patients under cancer therapy, which could have a positive impact on potential clinical and molecular o
"highlight2" >cardioP↑, A systematic review and meta-analysis reported that tomato and lycopene supplementation have positive effects on cardiovascular risk factors
"highlight2" >eff?, lycopene supplementation may have benefits in the oncology population during cancer treatment.
"highlight2" >PSA↓, Lycopene supplementation improved PSA levels in patients with an intermediate risk of cancer
"highlight2" >RenoP↑, Surprisingly, lycopene has been shown to improve renal makers of nephrotoxicity after cisplatin treatment

3285- Lyco,    Comparative evaluation of antiplatelet effect of lycopene with aspirin and the effect of their combination on platelet aggregation: An in vitro study
- in-vitro, Nor, NA
"highlight2" >*AntiAg↑, All the concentrations of lycopene (4–12 μmol/L) exhibited reduction in maximum platelet aggregation induced by aggregating agents ADP and collagen
"highlight2" >*eff↑, Four μmol/L of lycopene combined with 140 μmol/L and 70 μmol/L aspirin showed greater inhibition of platelets as compared to aspirin 140 μmol/L alone, against both ADP and collagen.

3286- Lyco,    Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation
- in-vitro, Nor, NA
"highlight2" >*AntiAg↑, We found that lycopene concentration-dependently (2–12 μmol/L) inhibited platelet aggregation in human platelets stimulated by agonists.

3287- Lyco,    Recent technological strategies for enhancing the stability of lycopene in processing and production
- Review, NA, NA
"highlight2" >*eff↑, With tangerine tomato juice we observed a marked 8.5-fold increase in lycopene bioavailability compared to red tomato juice was about 8.5 times than that of red tomato juice

3268- Lyco,    Lycopene as a Natural Antioxidant Used to Prevent Human Health Disorders
- Review, AD, NA
"highlight2" >*BioAv↓, Lycopene bioavailability can be decreased by ageing, and some of the pathological states, such as cardiovascular diseases (CVDs)
"highlight2" >*AntiCan↑, For instance, it has been shown that a higher dietary intake and circulating concentration of lycopene have protective effects against prostate cancer (PCa), in a dose-dependent way
"highlight2" >*ROCK1↓, It remarkably lessened the expression of ROCK1, Ki-67, ICAM-1 and ROCK2,
"highlight2" >*Ki-67↓,
"highlight2" >*ICAM-1↓,
"highlight2" >*cardioP↑, Lycopene is a cardioprotective nutraceutical.
"highlight2" >*antiOx↑, Lycopene is a well-known antioxidant.
"highlight2" >*NQO1↑, Furthermore, lycopene supplementation improves mRNA expressions of the NQO-1 and HO-1 as antioxidant enzymes.
"highlight2" >*HO-1↑,
"highlight2" >*TNF-α↓, downregulate inflammatory cytokines (i.e., TNF-α, and IL-1β) in the hippocampus of the mice.
"highlight2" >*IL22↓,
"highlight2" >*NRF2↑, Lycopene decreased neuronal oxidative damage by activating Nrf2, as well as by inactivating NF-κB translocation in H2O2-related SH-SY5Y cell model
"highlight2" >*NF-kB↓,
"highlight2" >*MDA↓, significantly reduced the malondialdehyde (MDA)
"highlight2" >*Catalase↑, Furthermore, it improved the catalase (CAT), superoxide dismutase (SOD), and GSH levels, and antioxidant capacity [109].
"highlight2" >*SOD↑,
"highlight2" >*GSH↑,
"highlight2" >*cognitive↑, Lycopene administration considerably improved cognitive defects, noticeably reduced MDA levels and elevated GSH-Px activity, and remarkably reduced tau
"highlight2" >*tau↓,
"highlight2" >*hepatoP↑, Lycopene was also found to be effective against hepatotoxicity by acting as an antioxidant, regulating total glutathione (tGSH) and CAT concentrations
"highlight2" >*MMP2↑, It also elevated MMP-2 down-regulation
"highlight2" >*AST↓, lowering the liver enzymes levels, like aspartate transaminase (AST), alanine transaminase (ALT), LDL, free fatty acid, and MDA.
"highlight2" >*ALAT↓,
"highlight2" >*P450↑, Moreover, tomato powder has been shown to have a protective agent against alcohol-induced hepatic injury by inducing cytochrome p450 2E1
"highlight2" >*DNAdam↓, lycopene decreased DNA damage
"highlight2" >*ROS↓, It has been revealed that they inhibited ROS production, protected antioxidant enzymes, and reversed hepatotoxicity in rats’ liver
"highlight2" >*neuroP↑, lycopene consumption relieved cognitive defects, age-related memory loss, neuronal damage, and synaptic dysfunction of the brain.
"highlight2" >*memory↑,
"highlight2" >*Ca+2↓, Lycopene suppressed the 4-AP-invoked release of glutamate and elevated intra-synaptosomal Ca2+ level.
"highlight2" >*Dose↝, an in vivo study revealed that lycopene (6.5 mg/day) was effective against cancer in men [147]. However, lycopene dose should be increased up to 10 mg/day, in the case of advanced PCa.
"highlight2" >*Dose↑, lycopene supplementation (15 mg/day, for 12 weeks) in an old aged population improved immune function through increasing natural killer cell activity by 28%
"highlight2" >*Dose↝, Finally, according to different epidemiological studies, daily lycopene intake can be suggested to be 2 to 20 mg per day
"highlight2" >*toxicity∅, A toxicological study on rats showed the no-observed-adverse-effect level at the highest examined dose (i.e., 1.0% in the diet)
"highlight2" >PGE2↓, Lycopene doses of 0, 10, 20, and 30 µM were used to treat human colorectal cancer cell. Prostaglandin E2 (PGE2), and NO levels declined after lycopene administration,
"highlight2" >CDK2↓, Treatment with lycopene reduced cell hyperproliferation induced by UVB and ultimately promoted apoptosis and reduced CDK2 and CDK4 complex in SKH-1 hairless mice
"highlight2" >CDK4↓,
"highlight2" >STAT3↓, lycopene reduced the STAT3 expression in ovarian tissues
"highlight2" >NOX↓, (SK-Hep-1) cells and indicated a substantial reduction in NOX activity. Moreover, it inhibits the protein expression of NOX4, NOX4 mRNA and ROS intracellular amounts
"highlight2" >NOX4↓,
"highlight2" >ROS↓,
"highlight2" >*SREBP1↓, Lycopene decreases the fatty acid synthase (FAS), sterol regulatory element-binding protein 1c (SREBP-1c), and Acetyl-CoA carboxylase (ACC1) expression in HFD mice.
"highlight2" >*FASN↓,
"highlight2" >*ACC↓,

3529- Lyco,    The antioxidant and anti-inflammatory properties of lycopene in mice lungs exposed to cigarette smoke
- in-vivo, Nor, NA
"highlight2" >*antiOx↑, Lycopene is a carotenoid with known antioxidant and anti-inflammatory properties.
"highlight2" >*Inflam↓,
"highlight2" >*ROS↓, Lycopene concentrations of 1 μM and 2 μM were able to reduce the production of ROS in 24 h compared with CS.
"highlight2" >*TNF-α↓, There was an increase in the levels of tumor necrosis factor-α, interferon-γ and interleukin-10 after exposure to CS, and these effects were suppressed by both doses of lycopene.
"highlight2" >*IFN-γ↓,
"highlight2" >IL10↓,

3530- Lyco,    Lycopene Scavenges Cellular ROS, Modulates Autophagy and Improves Survival through 7SK snRNA Interaction in Smooth Muscle Cells
- in-vitro, Stroke, NA
"highlight2" >*ROS↓, The reactive oxygen species (ROS) were reduced from 8 fold to 3 fold post addition of lycopene for 24 h.
"highlight2" >*antiOx↑, Lycopene administration during ischemic heart disease might improve the functions of the smooth muscle cells and 7SK snRNA might be involved in the binding of lycopene and its antioxidant protective effects.
"highlight2" >*TNF-α↓, Addition of Lycopene to the media showed diminished TNF-α expression (p < 0.0429) compared to the stressed group.

3531- Lyco,    Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system
- in-vivo, Nor, NA
"highlight2" >*NRF2↑, After LYC intervened in the body, it activated Nrf2 nuclear translocation and its downstream HO-1 and NQO1 antioxidant signaling pathways
"highlight2" >*HO-1↑, Lycopene activates Nrf2-HO-1 antioxidant pathway to inhibit oxidative stress injury induced by AAI exposure in NRK52E cells
"highlight2" >*NQO1↑,
"highlight2" >*ROS↓, LYC inhibited ROS production by renal tubular epithelial cells, and alleviated mitochondrial damage.
"highlight2" >*mtDam↓,
"highlight2" >*Bcl-2↑, LYC was able to up-regulate the expression of Bcl-2, down-regulate Bax expression and inhibit the activation of cleaved forms of Caspase-9 and Caspase-3, which finally attenuated the apoptosis
"highlight2" >*BAX↓,
"highlight2" >*Casp9↓,
"highlight2" >*Casp3↓,
"highlight2" >*Apoptosis↓,
"highlight2" >*RenoP↑, Interestingly, there was a significant improvement in damaged renal tissue in mice with AAN after lycopene intervention
"highlight2" >*lipid-P↓, lycopene significantly decreased the expression of AAI-induced lipid peroxidation product (MDA), and increased the expression of antioxidant enzyme systems (T-AOC, SOD, and GSH-PX)
"highlight2" >*SOD↑,
"highlight2" >*GPx↑,
"highlight2" >*Inflam↓, Lycopene improves inflammatory responses in the kidneys of AAN mice
"highlight2" >*TNF-α↓, TNF-α, IL-6, IL-10, was increased and the expression of IL-12 was decreased in the kidneys of model mice compared with the control group. However, LYC intervention reversed the expression of these genes in a dose-dependent manner
"highlight2" >*IL6↓,
"highlight2" >*IL10↓,

3532- Lyco,    Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2pathway in a cell model of Alzheimer’s disease
- in-vitro, AD, NA
"highlight2" >*ROS↓, Lycopene alleviated OS and apoptosis, activated the PI3K/Akt/Nrf2 signaling pathway, upregulated antioxidant and antiapoptotic proteins and downregulated proapoptotic proteins.
"highlight2" >*PI3K↑,
"highlight2" >*Akt↑,
"highlight2" >*NRF2↑,
"highlight2" >*antiOx↑,
"highlight2" >*Aβ↓, Lycopene possibly prevents Aβ-induced damage by activating the PI3K/Akt/Nrf2 signaling pathway and reducing the expression of BACE in M146L cells.
"highlight2" >*Apoptosis↓, Lycopene alleviates apoptosis in M146L cells
"highlight2" >*neuroP↑, lycopene shows the neuroprotective effects of antioxidative damage and antiapoptotic by reducing the phosphorylation of PI3K/Akt

3533- Lyco,  Chemo,    Lycopene and chemotherapy toxicity
- Review, Var, NA
"highlight2" >*ROS↓, Lycopene is a major carotenoid present in tomatoes, and it is a potent antioxidant that may provide protection against cellular damage caused by ROS.
"highlight2" >*antiOx↑,
"highlight2" >*chemoP↑, Lycopene may reduce or prevent the side effects of chemotherapy due to its antioxidant and anti-inflammatory properties.
"highlight2" >*Inflam↓,

3816- Lyco,  Lut,  Zeax,    Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults
- Review, AD, NA
"highlight2" >*Risk↓, high serum levels of lycopene and lutein+zeaxanthin at baseline were associated with a lower risk of AD mortality after adjustment for potential covariates.

3828- Lyco,    Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2pathway in a cell model of Alzheimer's disease
- in-vitro, AD, M146L
"highlight2" >*ROS↓, Lycopene alleviated OS and apoptosis, activated the PI3K/Akt/Nrf2 signaling pathway, upregulated antioxidant and antiapoptotic proteins and downregulated proapoptotic proteins.
"highlight2" >*PI3K↑,
"highlight2" >*Akt↑,
"highlight2" >*NRF2↓,
"highlight2" >*antiOx↑,
"highlight2" >*BACE↓, lycopene inhibited β -secretase (BACE) activity in M146L cells.
"highlight2" >*MDA↓,

4227- Lyco,    Lycopene Alleviates Depression-Like Behavior in Chronic Social Defeat Stress-Induced Mice by Promoting Synaptic Plasticity via the BDNF-TrkB Pathway
- in-vivo, NA, NA
"highlight2" >*BDNF↑, suggesting that lycopene may enhance synaptic plasticity via the BDNF–TrkB/pTrkB signaling pathway.
"highlight2" >*TrkB↑,
"highlight2" >*PSD95↑, mRNA expression levels of PSD‐95 and Syn in the hippocampus of the CSDS + LYC group mice were substantially upregulated compared to the model group

4228- Lyco,    A review for the pharmacological effect of lycopene in central nervous system disorders
- Review, AD, NA - Review, Park, NA
"highlight2" >*cognitive↑, Lycopene also improves cognition and memory ability of rodents in different pathological conditions, such as diabetes, colchicine exposure, high-fat diet (HFD), and aging.
"highlight2" >*memory↑,
"highlight2" >*Inflam↓, inhibition of oxidative stress and neuroinflammation, inhibition of neuronal apoptosis, and restoration of mitochondrial function have been shown to mediate the neuroprotective effects of lycopene.
"highlight2" >*Apoptosis↓,
"highlight2" >*ROS↓,
"highlight2" >*neuroP↑,
"highlight2" >*NF-kB↓, inhibition of nuclear factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK), activation of the nuclear factor erythroid 2-related factor (Nrf2) and brain-derived neurotrophic factor (BDNF) signaling, and restoration of intracellular Ca2+ homeostasis,
"highlight2" >*JNK↓,
"highlight2" >*NRF2↑,
"highlight2" >*BDNF↑,
"highlight2" >*MDA↓, 8 weeks of lycopene treatment (5 mg/kg) has been shown to reverse malondialdehyde (MDA) increase and glutathione peroxidase (GSH-Px) decrease in serum in tau transgenic mice expressing P301 L mutation
"highlight2" >*GPx↑,

4229- Lyco,    Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in β-amyloid induced Alzheimer׳s disease
- in-vivo, AD, NA
"highlight2" >*antiOx↑, beneficial therapeutic effects, which include anti-oxidant, neuro-protective and anti-cancer effects
"highlight2" >*neuroP↑,
"highlight2" >*AntiCan↑,
"highlight2" >*memory↑, Chronic administration of lycopene resulted in an improvement in memory retention, attenuation of mitochondrial-oxidative damage, reduced neuro-inflammation and restoration of BDNF level in β-A1-42 treated rats.
"highlight2" >*ROS↓,
"highlight2" >*BDNF↑,
"highlight2" >*cognitive↑, lycopene helps to protect β-A1-42 induced cognitive dysfunction and modulates amyloidogenesis.

4230- Lyco,    Supplementation of lycopene attenuates oxidative stress induced neuroinflammation and cognitive impairment via Nrf2/NF-κB transcriptional pathway
- in-vivo, AD, NA
"highlight2" >*BDNF↑, LYC ameliorated histopathological damage and restored brain derived neurotrophic factor (BDNF) levels in the hippocampus of mice.
"highlight2" >*antiOx↑, LYC also significantly elevated antioxidant enzymes activities and reduced levels of inflammatory cytokines in the d-galactose-treated mice serum.
"highlight2" >*Inflam↓,
"highlight2" >*HO-1↑, LYC treatment activated the mRNA expressions of antioxidant enzymes HO-1 and NQO-1, and downregulated inflammatory cytokines IL-1β and TNF-α
"highlight2" >*NQO1↑,
"highlight2" >*IL1β↓,
"highlight2" >*TNF-α↓,
"highlight2" >*ROS↓, LYC attenuated neuronal oxidative damage through activation of Nrf2 signaling
"highlight2" >*NRF2↑,
"highlight2" >*cognitive↑, LYC could ameliorate oxidative stress induced neuroinflammation and cognitive impairment possibly via mediating Nrf2/NF-κB transcriptional pathway.
"highlight2" >*BBB↑, LYC exerts antioxidant and anti-inflammatory effects both in vitro and in vivo and possesses blood brain barrier permeability

1716- Lyco,    Anti-inflammatory Activity of β-Carotene, Lycopene and Tri-n-butylborane, a Scavenger of Reactive Oxygen Species
- in-vitro, AML, RAW264.7
"highlight2" >antiOx↑, carotenoids β-carotene and lycopene are antioxidants that not only quench singlet oxygen but also inhibit lipid peroxidation
"highlight2" >lipid-P↓,
"highlight2" >ROS↑, These findings could explain the intriguing pro-oxidant and cytotoxic activity of β-carotene.
"highlight2" >Dose↑, new radical peaks then becoming slightly but reproducibly evident at concentrations over 10 mM

1013- Lyco,    Lycopene induces apoptosis by inhibiting nuclear translocation of β-catenin in gastric cancer cells
- in-vitro, GC, AGS
"highlight2" >Apoptosis↑,
"highlight2" >DNAdam↑,
"highlight2" >Bax:Bcl2↑,
"highlight2" >ROS↓, AGS cells. The results showed that lycopene reduces the levels of ROS
"highlight2" >β-catenin/ZEB1↓,
"highlight2" >p‑GSK‐3β↓,
"highlight2" >APC↑,
"highlight2" >β-TRCP↑,
"highlight2" >cMyc↓,
"highlight2" >cycD1↓,

1041- Lyco,  immuno,    Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells
- in-vivo, Lung, NA
"highlight2" >TumVol↓, combined lycopene and anti-PD-1 reduced the tumor volume and weight compared to control treatment.
"highlight2" >TumW↓,
"highlight2" >eff↑, lycopene could assist anti-PD-1 to elevate the levels of interleukin (IL)-1 and interferon (IFN) γ while reduce the levels of IL-4 and IL-10
"highlight2" >IL1↑,
"highlight2" >IFN-γ↑,
"highlight2" >IL4↓,
"highlight2" >IL10↓,

1126- Lyco,    Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway
- vitro+vivo, Oral, NA
"highlight2" >TumCP↓,
"highlight2" >TumCMig↓,
"highlight2" >TumCI↓,
"highlight2" >Apoptosis↑,
"highlight2" >EMT↓,
"highlight2" >PI3K↓,
"highlight2" >Akt↓,
"highlight2" >mTOR↓,
"highlight2" >E-cadherin↓,
"highlight2" >BAX↑,
"highlight2" >N-cadherin↓,
"highlight2" >p‑PI3K↓,
"highlight2" >p‑Akt↓,
"highlight2" >p‑mTOR↓,
"highlight2" >Bcl-2↓,

1708- Lyco,    The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies
- Review, Var, NA
"highlight2" >OS↑, reduced prostate cancer-specific mortality in men at high risk for prostate cancer
"highlight2" >ChemoSen↑, improved the response to docetaxel chemotherapy in advanced castrate-resistant prostate cancer
"highlight2" >QoL↑, lycopene improved the quality of life, and provided relief from bone pain and control of lower urinary tract symptoms
"highlight2" >PSA∅, PSA stabilisation in prostate cancer
"highlight2" >eff↑, Lycopene co-supplementation with vitamin E also showed an improvement in the results of prostate cancer treatment
"highlight2" >AntiCan↑, lycopene intake showed a strong protective effect against stomach cancer, regardless of H. pylori status
"highlight2" >AntiCan↑, A lycopene-rich diet was shown to reduce the incidence of pancreatic cancer in humans by 31%
"highlight2" >angioG↓,
"highlight2" >VEGF↓,
"highlight2" >Hif1a↓,
"highlight2" >SOD↑,
"highlight2" >Catalase↑,
"highlight2" >GPx↑,
"highlight2" >GSH↑,
"highlight2" >GPx↑,
"highlight2" >GR↑,
"highlight2" >MDA↓,
"highlight2" >NRF2↑,
"highlight2" >HO-1↑,
"highlight2" >COX2↓,
"highlight2" >PGE2↓,
"highlight2" >NF-kB↓,
"highlight2" >IL4↑,
"highlight2" >IL10↑,
"highlight2" >IL6↓,
"highlight2" >TNF-α↓,
"highlight2" >PPARγ↑,
"highlight2" >TumCCA↑, G(0)/G(1) phase
"highlight2" >FOXO3↓,
"highlight2" >Casp3↑,
"highlight2" >IGF-1↓, breast cancer,crc
"highlight2" >p27↑,
"highlight2" >STAT3↓,
"highlight2" >CDK2↓,
"highlight2" >CDK4↓,
"highlight2" >P21↑,
"highlight2" >PCNA↓,
"highlight2" >MMP7↓,
"highlight2" >MMP9↓,

1709- Lyco,    Lycopene prevents carcinogen-induced cutaneous tumor by enhancing activation of the Nrf2 pathway through p62-triggered autophagic Keap1 degradation
- in-vitro, Nor, JB6
"highlight2" >*antiOx↑, Lycopene stimulated the activation of antioxidant enzymes and the translocation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) that predominantly maintained intracellular redox equilibrium
"highlight2" >*NRF2↑, Lycopene activated the Nrf2 pathway in the presence of carcinogens in vivo and in vitro
"highlight2" >*GSH/GSSG↓, Lycopene also rebalanced the GSH/GSSG ratio, partly representing the cellular redox condition commendably
"highlight2" >*Catalase↝, catalase (CAT), glutathione reductase (GR), superoxide dismutase (SOD), and glutathione peroxidase (GPx), lower activities of these enzymes were reversed by this compound
"highlight2" >*GR↝,
"highlight2" >*SOD↝,
"highlight2" >*GPx↝,
"highlight2" >*GSH↑, mRNA levels of GSH and these antioxidant substances were also up-regulated significantly by lycopene pretreatment
"highlight2" >*Keap1↓, Lycopene induced activation of Nrf2 by reducing Keap1 protein
"highlight2" >*p62↑, lycopene induced p62 binding to Keap1, so Keap1 degradation was mediated by p62

1710- Lyco,    Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases
- Review, CardioV, NA
"highlight2" >antiOx↓, Lycopene is a potent antioxidant that fights ROS and, subsequently, complications.
"highlight2" >ROS↓,
"highlight2" >BP↓, It reduces blood pressure via inhibiting the angiotensin-converting enzyme and regulating nitrous oxide bioavailability.
"highlight2" >LDL↓, important role in lowering of LDL (low-density lipoproteins) and improving HDL (high-density lipoproteins) levels to minimize atherosclerosis
"highlight2" >*toxicity∅, Lycopene is a natural substance that may be used in high doses as a dietary supplement without causing harm to human health or physiology
"highlight2" >eff↑, Thermal food processing, particularly in the presence of cooking oils, causes lycopene to micellize and enhance its intestinal absorption rate by a factor of ten
"highlight2" >ROS↑, As a pro-oxidant, lycopene may have both good and negative impacts in biological systems, as well as influence the course of human illnesses.
"highlight2" >*Half-Life↑, Plasma lycopene has a half-life of 12–33 days in the human body
"highlight2" >*BioAv↓, Tomato lycopene is not easily absorbed since it is integrated into the nutritional matrix.
"highlight2" >*BioAv↑, Clinical research demonstrates that heat-processed tomato products absorb lycopene more quickly than raw sources, and that adding oil increases absorption
"highlight2" >*antiOx↑, Lycopene’s ability to protect against oxidative stress has been established

1711- Lyco,    Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review
- Review, Var, NA
"highlight2" >ROS↑, exposure to high doses of carotenoids has a pro-oxidant effect
"highlight2" >Dose↓, lycopene, an intake of 5 to 7 mg per day was recommended for healthy people to maintain the circulating levels of this carotenoid, in order to combat oxidative stress and prevent chronic diseases
"highlight2" >Dose↑, higher concentrations of lycopene (35–75 mg/day) may be required when there is a disease, such as cancer and cardiovascular diseases.
"highlight2" >antiOx↑, main protective effect of lycopene is due to its antioxidant effect through the inactivation of ROS and the extinction of free radicals
"highlight2" >P450↓, significant decrease in cytochrome P450 2E1
"highlight2" >TNF-α↓, TNF-α, IL-1β, and IL-12) were also found
"highlight2" >IL1β↓,
"highlight2" >IL12↓,

1712- Lyco,    Lycopene Protects against Smoking-Induced Lung Cancer by Inducing Base Excision Repair
- in-vitro, Lung, A549
"highlight2" >ROS↓, Conclusions: Lycopene treatment at a lower dosage could inhibit smoke-induced oxidative stress and promote genome stability
"highlight2" >ROS↑, we found that lycopene only exerted antioxidative effects at low-dosage, while such beneficial effects were diminished at high-dosage
"highlight2" >eff↑, suggesting an increased carotenoid uptake in the cells under oxidative stress

1713- Lyco,    Lycopene: A Potent Antioxidant with Multiple Health Benefits
- Review, Nor, NA
"highlight2" >*antiOx↑, As one of the most potent antioxidants, its capacity to neutralise singlet oxygen is double that of ?-carotene, ten times greater than that of ?-tocopherol, and one hundred and twenty-five times more effective than glutathione
"highlight2" >*ROS⇅, lycopene acts as an antioxidant in systems that produce singlet oxygen but behaves as a pro-oxidant in systems that create peroxide
"highlight2" >*Dose↝, In low doses, it acts as an antioxidant, but at high doses, it acts as a pro-oxidant
"highlight2" >*eff↑, In situation where there is an imbalance between antioxidant defences and ROS production, such as during inflammation or exposure to environmental toxins [91], lycopene may switch from its antioxidant role to a pro-oxidant role
"highlight2" >*LDL↓, Wistar rats given a high-fat diet and 50mg/kg body weight of lycopene daily for 3mths had significant reductions in plasma total cholesterol, triglycerides, and lLDL levels but increased HDL cholesterol
"highlight2" >*RenoP↑, shown to protect the kidney against chemically induced damage
"highlight2" >*Inflam↓, evidence is plentiful demonstrating the anti-inflammatory effects of lycopene both in vitro and in vivo
"highlight2" >neuroP↑, mice with Alzheimer's disease induced by ? amyloid, lycopene reduced oxidative stress, decreased neuronal loss, improved synaptic plasticity, and inhibited neuroinflammation
"highlight2" >Rho↓, lycopene treatment was demonstrated to have the potential to mitigate vascular arteriosclerosis in allograft transplantation by inhibiting Rho-associated kinases

1714- Lyco,    Lycopene reduces ovarian tumor growth and intraperitoneal metastatic load
- in-vitro, Ovarian, OV-MZ-6 - in-vivo, NA, NA
"highlight2" >ChemoSen↑, Lycopene treatment synergistically enhanced anti-tumorigenic effects of paclitaxel and carboplatin
"highlight2" >CA125↓, Lycopene decreased the expression of the ovarian cancer biomarker, CA125.
"highlight2" >ITGA5↓, down-regulated expression of ITGA5, ITGB1, MMP9, FAK, ILK and EMT markers, decreased protein expression of integrin α5 and reduced activation of MAPK.
"highlight2" >ITGB1↓,
"highlight2" >MMP9↓,
"highlight2" >FAK↓,
"highlight2" >EMT↓,
"highlight2" >MAPK↓,
"highlight2" >MMP9↓, Levels of MMP9 in serum and ascites were reduced upon lycopene prevention
"highlight2" >antiOx↑, The antioxidant properties of lycopene have been reported for the prevention and treatment of different tumor entities, especially in prostate cancer
"highlight2" >Ki-67↓, expression of Ki67 in tumor tissues was lowered upon lycopene treatment compared to the placebo
"highlight2" >MAPK↓, reduced the protein expression of integrin α5 and activation of MAPK signaling

1715- Lyco,    Pro-oxidant Actions of Carotenoids in Triggering Apoptosis of Cancer Cells: A Review of Emerging Evidence
- Review, Var, NA
"highlight2" >antiOx↑, Carotenoids are well known for their potent antioxidant function in the cellular system.
"highlight2" >ROS↑, However, in cancer cells with an innately high level of intracellular reactive oxygen species (ROS), carotenoids may act as potent pro-oxidant molecules and trigger ROS-mediated apoptosis
"highlight2" >ChemoSen↑, when carotenoids are delivered with ROS-inducing cytotoxic drugs, they can minimize the adverse effects of these drugs on normal cells by acting as antioxidants without interfering with their cytotoxic effects on cancer cells as pro-oxidants
"highlight2" >selectivity↑, In cancer cells with innately high intracellular ROS levels, carotenoids may act as pro-oxidants and trigger ROS-mediated apoptosis of cancer cells.
"highlight2" >eff↓, However, under high oxygen tension conditions (e.g., in the lungs of smokers), β-carotene shows tumor-promoting effects.
"highlight2" >Casp3↑,
"highlight2" >Casp7↑,
"highlight2" >Casp9↑,
"highlight2" >P53↑,
"highlight2" >BAX↑,
"highlight2" >DNAdam↑,
"highlight2" >mtDam↑, mitochondrial dysfunction
"highlight2" >eff↑, Astaxanthin co-treatment with β-carotene and lutein (equimolar 5 µM each)

3267- Lyco,    Lycopene inhibits angiogenesis both in vitro and in vivo by inhibiting MMP-2/uPA system through VEGFR2-mediated PI3K-Akt and ERK/p38 signaling pathways
- in-vitro, Nor, HUVECs
"highlight2" >*VEGF↓, highest dose used (400 μg/plug) completely inhibited the formation of vascular endothelial cells induced by vascular endothelial growth factor (VEGF).
"highlight2" >*MMP2↓, lycopene inhibited tube formation, invasion, and migration in HUVECs, and such actions were accompanied by reduced activities of matrix metalloproteinase-2, urokinase-type plasminogen activator, and protein expression of Rac1
"highlight2" >*uPA↓,
"highlight2" >*Rac1↑,
"highlight2" >*TIMP2↑, and by enhancing protein expression of tissue inhibitors of metalloproteinase-2 and plasminogen activator inhibitor-1.
"highlight2" >*p38↓, lycopene attenuated VEGF receptor-2 (VEGFR2)-mediated phosphorylation of extracellular signal-regulated kinase (ERK), p38, and Akt as well as protein expression of PI3K.
"highlight2" >*Akt↓,
"highlight2" >*angioG↓, anti-angiogenic effect of lycopene both in vitro and in vivo.

1717- Lyco,    Potential Role of Carotenoids as Antioxidants in Human Health and Disease
- Review, Var, NA
"highlight2" >antiOx↑, unique antioxidative properties.
"highlight2" >ROS⇅, The molecular mechanisms underlying these reactions are still not fully understood, especially in the context of the anti- and pro-oxidant activity of carotenoids
"highlight2" >ROS↑, antioxidant potential (e.g., lutein) or even leads to pro-oxidant behavior (i.e., zeaxanthin)

1718- Lyco,    The role of carotenoids in the prevention of human pathologies
- Review, Var, NA
"highlight2" >ROS⇅, Thus, in thymocytes, β-Carotene is an antioxidant at low oxygen pressure but a pro-oxidant at high oxygen concentrations
"highlight2" >ROS↑, lycopene may have also prooxidant activities depending on the type of oxidants used.

1719- Lyco,    Lycopene for the prevention and treatment of prostate disease.
- Review, Var, NA
"highlight2" >ROS⇅, Lycopene, a member of the carotenoid family, found commonly in red pigmented fruit and vegetables has been established as having strong antioxidant and pro-oxidant properties.

1720- Lyco,    Antioxidant and Pro-oxidant Activities of Carotenoids
- Review, Nor, NA
"highlight2" >ROS↑, lycopene (50 μM) exhibited pro-oxidant effects in in vitro cellular assays with several cancer cell lines (PC-3), (A549), (HeLa), (MCF-7), (A431), and (HepG2)

1721- Lyco,  RES,  VitC,    Lycopene, resveratrol, vitamin C and FeSO4 increase damage produced by pro-oxidant carcinogen 4-nitroquinoline-1-oxide in Drosophila melanogaster: Xenobiotic metabolism implications.
- in-vitro, Pca, PC3 - in-vitro, Lung, A549 - in-vitro, Cerv, HeLa - in-vitro, BC, MCF-7 - in-vitro, Liver, HepG2
"highlight2" >ROS↑, We propose that the basal levels of the XM's enzymes in the ST cross interacted with a putative pro-oxidant activity of the compounds added to the pro-oxidant effects of 4-NQO.

3260- Lyco,    Lycopene in human health
- Review, NA, NA
"highlight2" >*BioAv↝, Lycopene bioavailability is lower in raw sources than in thermal processed food sources.
"highlight2" >*BioAv↓, As a result of the low bioavailability of lycopene, its circulating levels are more suitable as prognostic data for health outcomes than its dietary intake values
"highlight2" >*ROS⇅, A beneficial or prejudicial cellular response by lycopene will depend on its antioxidant or prooxidant properties respectively, depending on the cellular and extracellular environment
"highlight2" >*BioAv↝, Thus, there is less bioavailability of lycopene in fresh tomatoes than in processed tomato products (such as pasteurized tomato juice, soup, sauce and ketchup)

3261- Lyco,    Lycopene and Vascular Health
- Review, Stroke, NA
"highlight2" >*Inflam↓, main activity profile of lycopene includes antiatherosclerotic, antioxidant, anti-inflammatory, antihypertensive, antiplatelet, anti-apoptotic, and protective endothelial effects, the ability to improve the metabolic profile, and reduce arterial stif
"highlight2" >*antiOx↑, It is a much more potent antioxidant than alpha-tocopherol (10 × more potent) or beta-carotene (twice as potent)
"highlight2" >*AntiAg↑, lycopene, protecting against myocardial infarction and stroke, is its antiplatelet activity
"highlight2" >*cardioP↑, favorable effect in patients with subclinical atherosclerosis, metabolic syndrome, hypertension, peripheral vascular disease, stroke and several other cardiovascular disorders
"highlight2" >*SOD↑, Lycopene modulates also the production of antioxidant enzymes, such as superoxide dismutase and catalase
"highlight2" >*Catalase↑,
"highlight2" >*ROS↓, By reducing oxidative stress and reactive oxygen species, lycopene increases the bioavailability of nitric oxide (NO), improves endothelium-dependent vasodilation and reduces protein, lipids, DNA, and mitochondrial damage (
"highlight2" >*mtDam↓,
"highlight2" >*cardioP↑, Lycopene exerts a cardioprotective effect against atrazine induced cardiac injury due to its anti-inflammatory effect, by blocking the NF-kappa B pathway and NO production
"highlight2" >*NF-kB↓,
"highlight2" >*NO↓,
"highlight2" >*COX2↓, downregulation of cyclooxygenase 2,
"highlight2" >*LDL↓, significant reductions in total and LDL cholesterol were revealed only at doses of, at least, 25 mg lycopene/day
"highlight2" >*eff↑, It was noticed that lycopene can potentiate the antiplatelet effect of aspirin, which requires low lycopene diet
"highlight2" >*ER Stress↓, Lycopene protects the cardiomyocytes by relieving ERS
"highlight2" >*BioAv↑, Lycopene is very bioavailable in the presence of oil, especially in monounsaturated oils, other dietary fats and processed tomato products
"highlight2" >*eff↑, Lycopene can increase the antioxidant properties of vitamin C, E, polyphenols and beta-carotene in a synergistic way
"highlight2" >*MMPs↓, figure 3, secretion of MMPs
"highlight2" >*COX2↓,
"highlight2" >*RAGE↓,

3262- Lyco,    Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1
- in-vitro, adrenal, SK-HEP-1
"highlight2" >TumCI↓, lycopene (1–10 μM) significantly inhibited SK-Hep-1 invasion (P<.05) and that this effect correlated with the inhibition of MMP-9 at the levels of enzyme activity
"highlight2" >MMP9↓,
"highlight2" >NF-kB↓, Lycopene also significantly inhibited the binding abilities of NF-κB and Sp1 and decreased, to some extent, the expression of insulin-like growth factor-1 receptor (IGF-1R) and the intracellular level of reactive oxygen species
"highlight2" >Sp1/3/4↓,
"highlight2" >IGF-1R↓,
"highlight2" >i-ROS↓,

3263- Lyco,    Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening
- in-vitro, Nor, H9c2 - in-vitro, Stroke, NA
"highlight2" >*Apoptosis↓, LP pretreatment significantly increased cell viability, reduced myocardial infarct size and decreased the apoptosis rate.
"highlight2" >*MMP↑, decrease of ΔΨm were attenuated by LP and the expressions of cytochrome c, APAF-1, cleaved caspase-9 and cleaved caspase-3 were also decreased by LP
"highlight2" >*Cyt‑c↓,
"highlight2" >*APAF1↓,
"highlight2" >*cl‑Casp9↓,
"highlight2" >*cl‑Casp3↓,
"highlight2" >*Bcl-2↑, LP treatment markedly increased Bcl-2 expression, decreased Bax expression and the Bax/Bcl-2 ratio.
"highlight2" >*BAX↓,
"highlight2" >cardioP↑, myocardial ischemia-reperfusion injury (MIRI). LP protects against MIRI by inhibiting MPTP opening, partly through the modulation of Bax and Bcl-2.

3264- Lyco,    Pharmacological potentials of lycopene against aging and aging‐related disorders: A review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
"highlight2" >*antiOx↑, Anti‐oxidative mechanism of lycopene
"highlight2" >*ROS↓, Lycopene inhibits ROS generation and subsequent oxidative stress by inducing antioxidant enzymes (SOD, CAT, GSH, GSH‐Px, and GST) and limiting MDA level and lipid peroxidation (LPO).
"highlight2" >*SOD↑,
"highlight2" >*Catalase↑,
"highlight2" >*GSH↑,
"highlight2" >*GSTs↑,
"highlight2" >*MDA↓,
"highlight2" >*lipid-P↓,
"highlight2" >*NRF2↑, Lycopene also prevents ROS release by upregulating Nrf2‐mediated HO‐1 levels and inhibiting iNOS‐activated NO generation
"highlight2" >*HO-1↑,
"highlight2" >*iNOS↓,
"highlight2" >*NO↓,
"highlight2" >*TAC↑, upregulating total antioxidant capacity (TAC) and direct inhibition of 8‐OHdG, NOX4.
"highlight2" >*NOX4↓,
"highlight2" >*Inflam↓, Anti‐inflammatory mechanism of lycopene.
"highlight2" >*IL1↓, IL‐1, IL‐6, IL‐8, IL‐1β, and TNF‐α release.
"highlight2" >*IL6↓,
"highlight2" >*IL8↓,
"highlight2" >*IL1β↓,
"highlight2" >*TNF-α↓,
"highlight2" >*TLR2↓, prevents inflammation by inhibiting toll‐like receptors TLR2 and TLR4 and endothelial adhesion molecules VCAM1 and ICAM‐1.
"highlight2" >*TLR4↓,
"highlight2" >*VCAM-1↓,
"highlight2" >*ICAM-1↓,
"highlight2" >*STAT3↓, inhibiting STAT3, NF‐κB, ERK pathway, and IL‐6 and TNF‐α release.
"highlight2" >*NF-kB↓,
"highlight2" >*ERK↓,
"highlight2" >*BP↓, Another clinical study demonstrated that consumption of raw tomato (200 g/day) could prevent type 2 diabetes‐associated cardiovascular diseases by lowering systolic and diastolic blood pressure, upregulating ApoA1, and downregulating ApoB levels
"highlight2" >ROS↓, lycopene suppresses the metastasis of the SK‐HEP‐1 cell line by NOX‐4 mRNA expression inhibition and the reactive ROS intracellular activity inhibition
"highlight2" >PGE2↓, Lycopene is also used to treat colorectal cancer cells in humans, and the introduction of lycopene decreases the prostaglandin E2 and nitric oxide levels
"highlight2" >cardioP↑, Lycopene‐rich foods can be highly beneficial in preventing cardiovascular diseases as lycopene is a potential source of antioxidants
"highlight2" >*neuroP↑, beneficial role of lycopene on aging‐related neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, has been confirmed in both experimental and clinical trials
"highlight2" >*creat↓, Several pre‐clinical studies reported that lycopene treatment significantly reduced serum urea and serum creatinine, as well as reversed various toxic chemical‐induced nephrotoxicity and oxidative damage by exhibiting excellent antioxidative properti
"highlight2" >*RenoP↑,

3265- Lyco,    Lycopene inhibits pyroptosis of endothelial progenitor cells induced by ox-LDL through the AMPK/mTOR/NLRP3 pathway
- in-vitro, Nor, NA
"highlight2" >*AMPK↑, through the activation of AMPK, which led to the inhibition of mTOR phosphorylation and subsequent downregulation of the downstream NLRP3 inflammasome.
"highlight2" >*mTOR↓,
"highlight2" >*NLRP3↓,
"highlight2" >*Pyro↓, Suppression of pyroptosis in EPCs by lycopene

3266- Lyco,    Effects of lycopene on number and function of human peripheral blood endothelial progenitor cells cultivated with high glucose
- in-vitro, Nor, NA
"highlight2" >*p38↓, lycopene blocked phosphorylation of p38 MAPK in EPCs
"highlight2" >*MAPK↓,

3534- QC,  Lyco,    Synergistic protection of quercetin and lycopene against oxidative stress via SIRT1-Nox4-ROS axis in HUVEC cells
- in-vitro, Nor, HUVECs
"highlight2" >*ROS↓, especially quercetin-lycopene combination (molar ratio 5:1), prevented the oxidative stress in HUVEC cells by reducing the reactive oxygen species (ROS) and suppressing the expression of NADPH oxidase 4 (Nox4), a major source of ROS production.
"highlight2" >*NOX4↓, Quercetin-lycopene combination could interact with SIRT1 to inhibit Nox4 and prevent endothelial oxidative stress
"highlight2" >*Inflam↓, quercetin-lycopene combination downregulated inflammatory genes induced by H2O2, such as IL-17 and NF-κB.
"highlight2" >*NF-kB↓, NF-κB p65 was activated by H2O2 but inhibited by the quercetin-lycopene combination.
"highlight2" >*p65↓,
"highlight2" >*SIRT1↑, quercetin and lycopene combination promoted the thermostability of Sirtuin 1 (SIRT1) and activated SIRT1 deacetyl activity
"highlight2" >*cardioP↑, The cardioprotective role of SIRT1
"highlight2" >*IL6↓, LYP: Q = 1:5), interacted with deacetylase SIRT1 to inhibit NF-κB p65 and Nox4 enzyme, downregulated inflammatory cytokines such as IL-6 and pro-inflammatory enzymes such as COX-2, and suppressed ROS elevation activated by H2O2.
"highlight2" >*COX2↓,


* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 54

Results for Effect on Cancer/Diseased Cells:
Akt↓,3,   p‑Akt↓,1,   angioG↓,1,   AntiCan↑,2,   antiOx↓,1,   antiOx↑,7,   APC↑,1,   Apoptosis↑,3,   BAX↓,1,   BAX↑,2,   Bax:Bcl2↑,1,   Bcl-2↓,1,   Bcl-2↑,1,   BioAv↓,2,   BioAv↑,1,   BP↓,1,   CA125↓,1,   cardioP↑,3,   Casp3↑,3,   Casp7↑,1,   Casp9↑,1,   Catalase↑,2,   CDK2↓,3,   CDK4↓,3,   chemoP↑,1,   ChemoSen↓,1,   ChemoSen↑,4,   CHK1↓,1,   Chk2↓,1,   cMyc↓,2,   COX2↓,3,   cycD1↓,4,   cycE↓,2,   DNAdam↓,1,   DNAdam↑,2,   Dose↓,1,   Dose↑,2,   Dose↝,1,   E-cadherin↓,1,   eff?,1,   eff↓,1,   eff↑,6,   EMT↓,2,   ERK↓,1,   EZH2↓,1,   FAK↓,1,   FOXO3↓,1,   G6PD↓,1,   Glycolysis↓,1,   GPx↑,4,   GR↑,1,   GSH↑,3,   GSK‐3β↓,1,   p‑GSK‐3β↓,1,   GSR↑,1,   GSTA1↑,1,   Hif1a↓,2,   HO-1↑,1,   IFN-γ↑,1,   IGF-1↓,1,   IGF-1R↓,1,   IL1↑,2,   IL10↓,2,   IL10↑,1,   IL12↓,1,   IL1β↓,2,   IL2↑,1,   IL4↓,1,   IL4↑,2,   IL6↓,3,   Inflam↓,1,   iNOS↓,1,   ITGA5↓,1,   ITGB1↓,1,   JAK1↓,1,   JNK↓,1,   Ki-67↓,1,   LDL↓,1,   lipid-P↓,2,   MAPK↓,2,   MDA↓,1,   MMP2↓,1,   MMP7↓,1,   MMP9↓,5,   MMPs↓,1,   MPO↓,1,   mtDam↑,1,   mTOR↓,2,   p‑mTOR↓,1,   N-cadherin↓,1,   neuroP↑,1,   NF-kB↓,5,   NO↓,1,   NOX↓,1,   NOX4↓,1,   NRF2↑,2,   OS↑,2,   P21↑,4,   p27↓,1,   p27↑,1,   P450↓,1,   P53↓,1,   P53↑,2,   p65↓,1,   cl‑PARP↑,1,   PCNA↓,3,   PGE2↓,5,   PI3K↓,1,   p‑PI3K↓,1,   PPARγ↑,2,   PSA↓,2,   PSA∅,1,   QoL↑,1,   RadioS↓,1,   RenoP↑,1,   Rho↓,1,   ROS↓,7,   ROS↑,9,   ROS⇅,3,   i-ROS↓,1,   selectivity↑,1,   SIRT1↑,1,   SOD↑,2,   Sp1/3/4↓,1,   STAT3↓,3,   TNF-α↓,4,   TNF-α↑,1,   TumCCA↑,2,   TumCI↓,3,   TumCMig↓,2,   TumCP↓,2,   TumMeta↑,1,   TumVol↓,1,   TumW↓,1,   VEGF↓,1,   Wnt↓,1,   β-catenin/ZEB1↓,2,   β-TRCP↑,1,   γH2AX↓,1,  
Total Targets: 139

Results for Effect on Normal Cells:
ACC↓,1,   Akt↓,2,   Akt↑,2,   ALAT↓,1,   AMPK↑,1,   angioG↓,1,   AntiAg↑,3,   AntiCan↑,2,   antiOx↑,15,   APAF1↓,1,   Apoptosis↓,4,   AST↓,1,   Aβ↓,1,   BACE↓,1,   BAX↓,2,   BBB↑,2,   Bcl-2↑,2,   BDNF↑,4,   BioAv↓,4,   BioAv↑,3,   BioAv↝,3,   BP↓,1,   Ca+2↓,1,   cardioP↑,5,   Casp3↓,1,   cl‑Casp3↓,1,   Casp9↓,1,   cl‑Casp9↓,1,   Catalase↑,3,   Catalase↝,1,   chemoP↑,1,   cognitive↑,4,   COX2↓,5,   creat↓,1,   Cyt‑c↓,1,   DNAdam↓,1,   Dose?,1,   Dose↑,1,   Dose↝,3,   eff↑,6,   ER Stress↓,1,   ERK↓,1,   FASN↓,1,   GPx↑,3,   GPx↝,1,   GR↝,1,   GSH↑,4,   GSH/GSSG↓,1,   GSR↑,1,   GSTs↓,1,   GSTs↑,1,   H2O2↓,1,   Half-Life↑,2,   hepatoP↑,1,   HO-1↑,5,   ICAM-1↓,2,   IFN-γ↓,1,   IL1↓,1,   IL10↓,1,   IL10↑,1,   IL1β↓,3,   IL22↓,1,   IL6↓,4,   IL8↓,1,   Inflam↓,10,   iNOS↓,2,   JNK↓,1,   Keap1↓,1,   Ki-67↓,1,   LDL↓,2,   lipid-P↓,3,   MAPK↓,2,   MDA↓,4,   memory↑,4,   MMP↑,1,   MMP2↓,1,   MMP2↑,1,   MMPs↓,1,   MPO↓,1,   mtDam↓,2,   mTOR↓,1,   neuroP↑,7,   NF-kB↓,6,   NLRP3↓,1,   NO↓,3,   NOX4↓,2,   NQO1↑,3,   NRF2↓,1,   NRF2↑,8,   p38↓,2,   P450↑,1,   p62↑,1,   p65↓,1,   PI3K↑,2,   PSD95↑,1,   Pyro↓,1,   Rac1↑,1,   radioP↑,1,   RAGE↓,1,   RenoP↑,3,   Risk↓,1,   ROCK1↓,1,   ROS↓,14,   ROS↑,1,   ROS⇅,3,   SIRT1↑,1,   SOD↑,5,   SOD↝,1,   SREBP1↓,1,   STAT3↓,1,   TAC↑,2,   tau↓,1,   TGF-β1↑,1,   TIMP2↑,1,   TLR2↓,1,   TLR4↓,1,   TNF-α↓,7,   toxicity∅,2,   TrkB↑,1,   uPA↓,1,   VCAM-1↓,1,   VEGF↓,1,   VitC↑,1,   VitE↑,1,  
Total Targets: 124

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:119  Target#:%  State#:%  Dir#:%
  wNotes=on  sortOrder:rid,rpid

 

Home Page